Cell Culture Sampling Device Market By Device Type (Closed Manual Sampling Systems, Automated Bioreactor Samplers, Micro-Volume Aseptic Sampling Devices, Analyzer-Connected Sampling Platforms, Sample Preparation & Storage Modules); By Component (Sampling Probes, Tubing & Connectors, Filters & Filtration Coils, Sample Bags & Bottles, Vials & Fraction Collectors, Disposable Fluid Paths, Software & Control Modules); By Automation Mode (Manual Closed Sampling, Semi-Automated Sampling, Fully Automated Multi-Reactor Sampling); By Bioreactor Scale (Microbioreactors, Benchtop Bioreactors, Pilot-Scale Bioreactors, Manufacturing-Scale Bioreactors, Parallel Multi-Reactor Systems); By Application (Monoclonal Antibody & Recombinant Protein Production, Cell & Gene Therapy Development, Vaccine Production, Process Development, Quality Control & In-Process Testing, Academic & Translational Research); By End User (Biopharmaceutical Companies, Contract Development and Manufacturing Organizations [CDMOs], Cell & Gene Therapy Developers, Academic & Research Institutes, Bioprocess Technology Providers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Cell Culture Sampling Device Market: Which Companies Are Shaping Automated Aseptic Sampling? Bioreactor Automation Expands the Cell Culture Sampling Revenue Base

The Global Cell Culture Sampling Device Market is projected to grow from USD 1.34 billion in 2025 to USD 2.33 billion by 2032, expanding at a CAGR of 8.2%, according to Strategic Market Research.

 

From Sample Withdrawal to a Recurring Bioprocess Revenue Model

The market covers devices and sterile assemblies used to withdraw representative samples from cell-culture vessels and prepare those samples for in-process analysis. Closed manual sampling systems, automated bioreactor samplers, probes, tubing, filters, sample bags, fraction collectors, vials, storage modules, and platform-specific disposable fluid paths form the core product base. Generic pipettes, standalone cell counters, analytical instruments, and bioreactors are excluded unless they are directly connected to the sampling workflow.

Commercial demand is determined by active bioreactors, parallel experiments, samples collected per run, minimum sample volume, and the number of sterile assemblies consumed. Automated platforms create periodic capital-equipment revenue, while tubing sets, filters, bags, probes, vials, software, maintenance, and validation support generate recurring sales. Patient numbers, prescriptions, and medical reimbursement do not measure this market because purchases are funded through process-development, manufacturing, automation, quality, and research budgets.

 

Manual Sampling Gives Way to Closed, Analyzer-Connected Workflows

Manual sample withdrawal is losing ground in laboratories that operate several bioreactors or require frequent analytical measurements. Operators must otherwise collect, label, dilute, filter, store, and transfer each sample. Automated systems reduce those repetitive steps and allow laboratories to maintain sampling schedules overnight or during weekends.

Closed sampling is also gaining value under contamination-control requirements. EU GMP Annex 1 states that sampling methods should not create contamination risk and recognizes closed and single-use systems as controls that reduce exposure and manual manipulation. Once a sterile assembly is qualified, replacing it can require compatibility work, documentation changes, and revalidation. That qualification burden supports repeat sales of platform-specific fluid paths and consumables.

The fastest technical movement is occurring at the connection between the bioreactor and the analyzer. Higher-value systems now combine sample withdrawal with dilution, filtration, cooled storage, and routing to cell counters, biochemical analyzers, HPLC, or LC-MS. Micro-volume research is opening a second development path for cell and gene therapy, where removing several milliliters can consume a meaningful share of a small culture.

 

Six Companies Competing for Control of the Sampling Workflow

Securecell, Merck, and Flownamics Lead Multi-Reactor Automation

Securecell AG competes in high-value, multi-reactor automation. Numera 3 can sample from up to 16 bioreactors, operate at intervals as frequent as six minutes, connect with as many as six analyzers, perform dilution up to 1:100, filter samples, and retain them under cooled conditions. Lucullus software links sample scheduling, analytical data, monitoring, and feedback control. Securecell launched Numera 3 in 2025 after introducing Integra1 64 and SampleBus in 2024, giving the company one of the most active recent development records in this niche.

Merck KGaA, operating through MilliporeSigma in the United States and Canada, combines automated sampling equipment with closed manual consumables. Its MAST Autosampling Solution can connect with up to 25 sample sources and four primary analytical destinations, while additional secondary destinations can be included. Merck also sells NovaSeptum sterile sampling products, allowing it to generate revenue from the platform, software, sample pilots, bags, bottles, syringes, and related assemblies. The combined equipment-and-consumables model gives Merck wider account coverage than suppliers focused on only one product category.

Flownamics is positioned as a modular integration specialist. Seg-Flow PS can operate independently or in parallel across as many as 16 bioreactors or sample streams. Its sample range of 0.25–50 mL and fully disposable closed fluid path support lower-volume development work and cell and gene therapy applications. The system can also send samples to several analytical devices through the company’s Director liquid handler. Flownamics benefits where laboratories operate mixed reactor and analyzer brands and do not want to adopt a single closed equipment ecosystem.

Eppendorf uses its bioreactor installed base to sell autosampling as an extension of existing process-development systems. Its Bioprocess Autosampler supports DASbox, DASGIP, SciVario twin, and BioFlo 320 platforms, stores up to 324 vials at 4–40°C, and works with culture volumes from approximately 60 mL to 10 L. The equipment can be retrofitted to selected existing systems, creating upgrade revenue without requiring full reactor replacement.

Sartorius has a narrower but valuable position in automated sample preparation. StreamLink CC 15 processes 24–48 samples from Ambr 15 and Ambr 250 bioreactors and supports throughput of up to 12 samples per hour. Sartorius reports that manual input in the stated workflow can fall from six hours to ten minutes. Clarification discs and purification membrane devices are consumed during operation, adding repeat revenue to the equipment sale.

Thermo Fisher Scientific is stronger in closed manual sampling and single-use fluid management than in integrated autosampling platforms. Its portfolio includes sampling assemblies for single-use and stainless-steel environments, including a 2 mm needle configuration, as well as sterile bottle, tubing, and bag assemblies. Thermo Fisher competes through configuration breadth, material consistency, existing single-use relationships, and supply availability rather than multi-reactor orchestration.

 

Platforms Gain Value by Preparing, Storing, and Routing Samples

Numera 3 represents the movement toward centralized sampling and analysis. One platform can coordinate several vessels, prepare samples differently for each test, and route them to multiple analyzers. Revenue extends into multiplexers, filtration coils, sampling sets, storage modules, analyzer interfaces, software, support, and replacement components rather than ending with the initial platform sale.

Merck’s MAST platform addresses larger process-development and manufacturing configurations. Its ability to push samples over distances exceeding 100 feet allows analytical equipment to remain outside production suites. In a supplier-reported Takeda implementation, three MAST systems were used for daily bioreactor sampling and online data acquisition. Merck reported a tenfold reduction in full-time-equivalent time, a tenfold reduction in experiment run time, tenfold faster analytical turnaround, and a 60% reduction in analysts required for the evaluated workflow.

Flownamics is developing around lower sample volumes, mixed-platform compatibility, and disposable paths. Seg-Flow PS can move samples up to 50 feet and can be paired with cell-free probes, fraction collectors, cooling devices, and analytical interfaces. Its 0.25 mL minimum volume places it closer to small-culture requirements than platforms beginning at several milliliters.

Eppendorf’s autosampler is differentiated by unattended storage. Up to 324 vials can be retained for later analysis, which is useful when analytical capacity is not available at the exact time of collection. Sartorius differentiates through preparation rather than collection alone. StreamLink converts raw cell-culture material into clarified or purified samples that are ready for critical-quality-attribute testing, making single-use filtration and purification components part of the revenue model.

 

Installed Platforms Turn Sterile Consumables into Long-Term Revenue

Workflow Ownership Protects Equipment, Software, and Disposable Sales

Competition is divided between integrated automated platforms and closed manual assemblies. Automated systems carry higher installation values because they combine reactor connectivity, scheduling, preparation, storage, software, and analyzer integration. Manual systems have a wider potential user base but face stronger price comparison when several suppliers can produce equivalent tubing, bag, syringe, and connector configurations.

Workflow ownership provides the strongest protection after installation. Sartorius and Eppendorf can sell sampling products into their existing bioreactor ecosystems. Merck can combine MAST with NovaSeptum consumables and broader single-use relationships. Securecell competes through sampling software and multi-analyzer control, while Flownamics gains access through compatibility with several third-party reactor and analytical platforms.

Consumables determine the lifetime value of installed systems. Sampling lines, filters, probes, vials, bags, and purification devices are consumed according to culture runs and sampling frequency. Sartorius specifies single-use Sartoclear discs and Sartobind membrane devices for StreamLink, while Securecell uses dedicated sampling sets and filtration coils. Supplier revenue can therefore increase with system utilization even when new platform orders slow.

Entry barriers are lower for a research prototype than for a validated commercial platform. Biopharmaceutical customers require sterile operation, consistent sample delivery, installation support, service, software maintenance, and long-term access to compatible disposables. A new device must prove that it can be manufactured and supported repeatedly, not only that it can collect an accurate sample.

 

Partnerships Link Sampling Platforms with Analytics and Cell-Therapy Development

Partnerships are increasingly focused on connecting the sampler with process software, analytical instruments, and cell-therapy development environments. Securecell partnered with Cell and Gene Therapy Catapult and DataHow in 2024 to integrate automated sampling, digitalization, process analytical technology, and process modeling into cell and gene therapy manufacturing. The collaboration gives Securecell access to an application where culture material is scarce and process data are difficult to collect.

Analyzer relationships also influence platform acceptance. Securecell, Merck, and Flownamics promote connections with cell counters, biochemical analyzers, chromatography systems, and LC-MS instruments. Established integrations reduce custom engineering and allow the sampling supplier to capture more of the workflow between collection and analytical measurement.

Merck’s work with Takeda provides evidence of adoption beyond a laboratory demonstration. The deployment connected repeated aseptic sampling with faster analytical data delivery during process development. Application partnerships of this kind provide performance evidence for labor reduction, sterility, and analytical turnaround, supporting wider adoption among biopharmaceutical manufacturers and CDMOs.

 

Micro-Volume Sampling Opens a New Cell-Therapy Device Category

Auto-CeSS Pushes Aseptic Sampling into Microliter Volumes

Micro-volume sampling is the most important emerging device category. A 2024 A*STAR program demonstrated automated aseptic sampling from 0.02 mL to 1.00 mL. The 2025 Auto-CeSS study reduced the minimum volume to 30 microliters and demonstrated sampling at 15-minute intervals from a 2 mL perfusion microbioreactor and an 8 mL gas-permeable culture vessel used for T-cell production. The platform remains pre-commercial, but it addresses a clear limitation of conventional samplers in small, high-value cultures.

Commercialization will depend on multiplexing, sterile disposable kits, qualification documentation, analyzer connectivity, and service. Research groups may become technology licensors, form specialist companies, or partner with established bioprocess suppliers that already have manufacturing and distribution infrastructure.

Sample-free monitoring creates a selective competitive threat. Repligen acquired 908 Devices’ desktop bioprocess analytics portfolio in March 2025, including MAVEN. MAVEN uses diffusion-based monitoring to measure glucose and lactate as frequently as every two minutes without withdrawing culture volume. It can replace physical samples for those two routine measurements, but cell counting, chromatography, molecular characterization, retained samples, and multi-analyte testing still require extracted material.

 

Smaller Samples and Automated Preparation Will Reshape Supplier Revenue

Micro-volume collection will push commercial systems below today’s common multi-milliliter range. Cell and gene therapy developers need frequent measurements without sacrificing scarce culture material. Suppliers that combine low sample loss with aseptic operation and multi-vessel connectivity can establish a distinct premium segment.

Automated preparation will capture more spending than sample withdrawal alone. Dilution, filtration, purification, cooled retention, and analyzer routing remove additional labor and create demand for proprietary filters, membranes, vials, and software modules. Platforms that stop at collection will face greater pressure from integrated competitors.

Closed disposable paths will remain the most stable recurring revenue category. Regulatory contamination control, customer qualification, and batch-risk exposure make validated assemblies difficult to replace. Regional production and dual-source capability will influence contracts alongside price.

In-line and sample-free sensors will reduce extracted sampling for a limited number of routine parameters. Automated sampling systems will remain necessary where physical material must be retained or prepared for complex analysis. The strongest suppliers will position sampling as part of a combined measurement strategy rather than compete directly with every in-line sensor.

 

Closed Platforms and Micro-Volume Systems Define the Next Competitive Cycle

The cell culture sampling device market is moving from isolated manual collection toward closed platforms that coordinate several bioreactors, prepare samples, preserve sterility, and connect directly with analytical instruments. Securecell and Merck are positioned for complex multi-source automation. Flownamics competes through modularity, lower sample volumes, and multi-brand compatibility. Eppendorf and Sartorius use established bioreactor ecosystems to capture upgrade and consumables revenue, while Thermo Fisher remains relevant in closed manual assemblies.

Micro-volume systems such as Auto-CeSS could create a new cell-therapy category, but commercial success will require more than a laboratory prototype. Suppliers must provide validated sterile paths, reliable disposables, analyzer integration, software, and long-term service.

Capital equipment establishes the installed base. Recurring fluid paths, filters, bags, vials, software, maintenance, and qualification support determine how much revenue each supplier captures over the life of the system. Companies that control both the sampling connection and the downstream preparation workflow will hold the strongest position as laboratories reduce manual handling and increase sampling frequency.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.34 Billion
Revenue Forecast in 2032	USD 2.33 Billion
Overall Growth Rate	CAGR of 8.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Device Type, By Component, By Automation Mode, By Bioreactor Scale, By Application, By End User, By Geography
By Device Type	Closed Manual Sampling Systems, Automated Bioreactor Samplers, Micro-Volume Aseptic Sampling Devices, Analyzer-Connected Sampling Platforms, Sample Preparation & Storage Modules
By Component	Sampling Probes, Tubing & Connectors, Filters & Filtration Coils, Sample Bags & Bottles, Vials & Fraction Collectors, Disposable Fluid Paths, Software & Control Modules
By Automation Mode	Manual Closed Sampling, Semi-Automated Sampling, Fully Automated Multi-Reactor Sampling
By Bioreactor Scale	Microbioreactors, Benchtop Bioreactors, Pilot-Scale Bioreactors, Manufacturing-Scale Bioreactors, Parallel Multi-Reactor Systems
By Application	Monoclonal Antibody & Recombinant Protein Production, Cell & Gene Therapy Development, Vaccine Production, Process Development, Quality Control & In-Process Testing, Academic & Translational Research
By End User	Biopharmaceutical Companies, Contract Development and Manufacturing Organizations [CDMOs], Cell & Gene Therapy Developers, Academic & Research Institutes, Bioprocess Technology Providers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Switzerland, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising adoption of bioreactor automation, stronger contamination-control requirements, growing use of closed and single-use sampling assemblies, increasing need for analyzer-connected workflows, micro-volume sampling demand in cell and gene therapy, and recurring revenue from sterile consumables
Customization Option	Available upon request